Today, CSI-Cancer is excited to announce it has entered into an exclusive license and collaboration agreement with Epic Sciences. The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions.
Read the press release
